We are live on ! Find out more
MDCO

Medicines Co
MDCO

Delisted

MDCO was delisted on the 3rd of January, 2020.

188 hedge funds and large institutions have $1.85B invested in Medicines Co in 2018 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 78 increasing their positions, 46 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 46

11% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 38

2% more funds holding

Funds holding: 184188 (+4)

21% less call options, than puts

Call options by funds: $43.2M | Put options by funds: $54.4M

33% less funds holding in top 10

Funds holding in top 10: 96 (-3)

35% less capital invested

Capital invested by funds: $2.83B → $1.85B (-$981M)

Holders
188
Holders Change
+4
Holders Change %
+2.17%
% of All Funds
4.19%
Holding in Top 10
6
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-33.33%
% of All Funds
0.13%
New
42
Increased
78
Reduced
46
Closed
38
Calls
$43.2M
Puts
$54.4M
Net Calls
-$11.2M
Net Calls Change
-$2.54M
Name Holding Trade Value Shares
Change
Change in
Stake
Invesco
26
Invesco
Georgia
$13.3M -$5.31M -228,386 -25%
Goldman Sachs
27
Goldman Sachs
New York
$13.1M +$5.59M +240,392 +54%
Citadel Advisors
28
Citadel Advisors
Florida
$11.2M +$10M +430,929 +280%
Principal Financial Group
29
Principal Financial Group
Iowa
$10.4M -$166K -7,140 -1%
JP Morgan Chase
30
JP Morgan Chase
New York
$10.4M -$2M -85,874 -14%
GIM
31
Granahan Investment Management
Massachusetts
$10M -$181K -7,785 -1%
First Eagle Investment Management
32
First Eagle Investment Management
New York
$8.56M +$2.19M +94,167 +27%
TCM
33
Tekla Capital Management
Massachusetts
$8.21M +$6.12M +263,151 +159%
UBS Group
34
UBS Group
Switzerland
$7.92M +$8.1M +348,310 +533%
AG
35
Artal Group
Luxembourg
$7.66M
Norges Bank
36
Norges Bank
Norway
$7.53M +$839K +36,088 +10%
USAA
37
United Services Automobile Association
Texas
$7.52M +$23.7K +1,020 +0.3%
Charles Schwab
38
Charles Schwab
California
$6.96M -$41.2K -1,770 -0.5%
Deutsche Bank
39
Deutsche Bank
Germany
$6.58M +$2.67M +114,862 +50%
EAM
40
Eventide Asset Management
Massachusetts
$6.41M +$7.79M +335,000 New
UBS AM
41
UBS AM
Illinois
$5.53M +$252K +10,853 +4%
TA
42
Teachers Advisors
New York
$4.94M +$9.12K +392 +0.2%
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$4.87M +$1.59M +68,195 +37%
HS
44
HighVista Strategies
Massachusetts
$4.49M -$789K -33,900 -13%
BC
45
Boxer Capital
California
$4.44M -$27.2M -1,168,000 -83%
AIMCA
46
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$4.29M +$2.95M +126,700 +130%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$3.74M +$820K +35,238 +22%
MFP
48
Michael F. Price
$3.64M +$4.42M +190,000 New
PPA
49
Parametric Portfolio Associates
Washington
$3.49M +$702K +30,195 +20%
PAM
50
Panagora Asset Management
Massachusetts
$3.32M -$1.3M -55,976 -24%

MDCO Hedge Fund Activity: Q4 2018 in Review

188 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q4 2018, worth a combined $1.85B — down 35% from $2.83B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new MDCO positions and 38 closed out — a net gain of 4 holders — while 78 added to existing stakes and 46 trimmed.

The largest buyer was HealthCor Management, adding an estimated $50.9M. The largest seller was PointState Capital, exiting entirely with an estimated $87.6M sold.

  • 188 institutional investors held Medicines Co (MDCO) as of Q4 2018, up from 184 in Q3 2018.
  • Funds reported $1.85B of Medicines Co stock for Q4 2018, down 35% quarter-over-quarter.
  • 42 funds opened new Medicines Co positions in Q4 2018 and 38 closed out, a net change of +4 holders.
  • The largest Medicines Co buyer in Q4 2018 was HealthCor Management, an estimated $50.9M added.
  • The largest Medicines Co seller in Q4 2018 was PointState Capital, an estimated $87.6M sold.

Based on aggregated 13F filings for Q4 2018.